Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp. (Nasdaq: DMAAR) is a blank-check company focused on the pharmaceutical and domestic drug manufacturing sector. On May 5, 2026, the company filed a Form 425 with the SEC, a communication type associated with proposed business combinations, indicating that DMAAR is actively engaged in a potential merger or acquisition process. The SPAC's thematic focus on U.S.-based drug production reflects a broader policy and investor emphasis on domestic pharmaceutical supply chain resilience. Sponsor details and additional deal terms are available in the underlying filing record. Sign up at SpacDesk for full data on DMAAR's filing history, deal status, and sector comparables.